Remdesivir, Given to Half of Hospitalized Covid Patients in U.S., Is Big Win for Gilead 鈥 Boosted by Taxpayers
With U.S. cases skyrocketing, demand for Gilead鈥檚 dark horse antiviral is only growing. Biden appointees propose potential legal tactics to tamp down the price for patients.